Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:16 PM
Ignite Modification Date:
2025-12-24 @ 12:16 PM
NCT ID:
NCT00898261
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Confirmed diagnosis of acute lymphoblastic leukemia
* Tissue banked on protocol ECOG-2993 meeting the following criteria:
* Leukemic blast cell population immunophenotyped in detail (e.g., including CD25) in ECOG's Immunophenotyping Reference Laboratory
* Flow cytometric analysis of gated blast cells reveals association with the B-cell lineage
* Mononuclear cell fraction used for RNA isolation contains 75-99% blasts (median 85%)
* Negative for TEL/AML1, MLL/AF4, and E2A/PBX1 by qualitative reverse transcription-polymerase chain reaction (RT-PCR)
* No FLT3 gene mutations
* BCR/ABL-positive samples meeting the following criteria:
* Presence of t(9;22)(q34;q11) by standard cytogenetics
* Detection of either p190 BCR/ABL or p210 BCR/ABL transcripts by qualitative RT-PCR
* Patients with genetic risk factors must meet the following criterion:
* Only a normal diploid karyotype is present in ≥ 15 metaphases by standard cytogenetics
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Maximum Age:
65 Years
Study:
NCT00898261
Study Brief:
Protocol Section:
NCT00898261